Multiple Sclerosis, Relapsing Remitting Clinical Trial
Official title:
Observational Study to Determine the Relationship Between the Degree of Disability and the Presence of Sexual Dysfunction and Between Sexual Dysfunction and the Quality of Life in Patients With Multiple Sclerosis (RRMS)
This is an observational, prospective, non-interventional, non-controlled study planned to
be conducted in subjects with Relapsing-Remitting Multiple Sclerosis (RRMS).
The purpose of this observational study is to determine the correlation between the degree
of disability and sexual dysfunction; and between the sexual dysfunction and the quality of
life (QoL) of subjects with Relapsing Remitting Multiple Sclerosis (RRMS) in Argentina.
Status | Completed |
Enrollment | 306 |
Est. completion date | May 2013 |
Est. primary completion date | May 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 22 Years and older |
Eligibility |
Inclusion Criteria: - Men and women > 21 years of age - Subjects with established diagnosis of RRMS according to the revised McDonald criteria - 2005 - Subjects with a diagnosis of RRMS for more than one year - The subject who have signed the Informed Consent Exclusion Criteria: - Subjects with no sexual experience - Subjects with other diseases associated to MS - Subjects with psychiatric diseases that could cause sexual dysfunction - Subjects with one relapse during the previous month - Use of antidepressants and/or corticosteroids during the previous month |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Argentina | Dr. Norma Deri | Buenos Aires |
Lead Sponsor | Collaborator |
---|---|
Merck KGaA | Merck Quimica Argentina S.A.I.C |
Argentina,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The correlation between the degree of disability and sexual dysfunction, and between the sexual dysfunction and the QoL of subjects | Mini-Mental State Examination (MMSE) Psychotropic-Related Sexual Dysfunction Questionnaire (PRSexDQ) Hamilton Rating Scale for Depression (HRSD) | Initial visit (Day 0) and each follow up visit upto the observation period of 24 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01080027 -
Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR)
|
N/A | |
Completed |
NCT02247310 -
BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon
|
N/A | |
Completed |
NCT00859482 -
Differential Immune Effects of Natalizumab
|
N/A | |
Completed |
NCT02638038 -
This is a Randomized Study Comparing Two Doses of INT131 ( 3 mg and 1 mg) Administered Orally (PO) Daily (QD) Versus Placebo 1 Tablet PO QD in Subjects With Treatment-naïve RRMS for ≤ 3 Years
|
Phase 2 | |
Completed |
NCT01080040 -
To Assess the Prevalence of Spasticity and the Impact on the Quality of Life in Multiple Sclerosis Patients
|
N/A |